Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Sell
37
QURE Quote, Financials, Valuation and Earnings
Last price:
$14.06
Seasonality move
:
7.88%
Day range:
$13.94 - $14.54
52-week range:
$3.73 - $19.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
23.78x
P/B ratio:
12.27x
Volume:
992.1K
Avg. volume:
3.7M
1-year change:
146.92%
Market cap:
$684.8M
Revenue:
$15.8M
EPS (TTM):
-$4.96
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$6.6M | -$0.89 | 194.09% | -62.87% | $30.54 |
|
ARGX
argenx SE
|
$726.3M | $1.92 | 58.02% | -44.75% | $701.57 |
|
MRUS
Merus NV
|
$9.2M | -$0.94 | -4.27% | -10.77% | $86.07 |
|
PHAR
Pharming Group
|
$64M | -$0.01 | 0.91% | -62.5% | $27.00 |
|
PHVS
Pharvaris NV
|
-- | -$0.77 | -- | -6.9% | $34.08 |
|
PRQR
ProQR Therapeutics NV
|
$9M | -$0.15 | 86% | -96.33% | $9.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$14.05 | $30.54 | $684.8M | -- | $0.00 | 0% | 23.78x |
|
ARGX
argenx SE
|
$640.52 | $701.57 | $38.3B | -- | $0.00 | 0% | 21.00x |
|
MRUS
Merus NV
|
$39.45 | $86.07 | $2.7B | -- | $0.00 | 0% | 67.53x |
|
PHAR
Pharming Group
|
$10.01 | $27.00 | $679M | -- | $0.00 | 0% | 2.60x |
|
PHVS
Pharvaris NV
|
$18.36 | $34.08 | $995.7M | -- | $0.00 | 0% | -- |
|
PRQR
ProQR Therapeutics NV
|
$2.37 | $9.17 | $251M | -- | $0.00 | 0% | 9.97x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QURE
uniQure NV
|
47.8% | -7.855 | 21.27% | 6.18x |
|
ARGX
argenx SE
|
-- | 0.387 | -- | 7.52x |
|
MRUS
Merus NV
|
-- | 1.670 | -- | 7.94x |
|
PHAR
Pharming Group
|
29.71% | -2.605 | 17.05% | 2.76x |
|
PHVS
Pharvaris NV
|
-- | -2.592 | -- | -- |
|
PRQR
ProQR Therapeutics NV
|
15.29% | -0.393 | 3.39% | 2.29x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QURE
uniQure NV
|
$1.3M | -$40.2M | -96.96% | -154.29% | -1215.48% | -$45.3M |
|
ARGX
argenx SE
|
$514.2M | $16.2M | -5.47% | -6.01% | 15.47% | -$147M |
|
MRUS
Merus NV
|
-- | -$72.2M | -47.97% | -47.97% | -613.59% | -$80.7M |
|
PHAR
Pharming Group
|
$68M | $4.1M | -5.33% | -8.24% | 6.03% | $9.4M |
|
PHVS
Pharvaris NV
|
-- | -$41.7M | -- | -- | -- | -$38.1M |
|
PRQR
ProQR Therapeutics NV
|
-- | -$9.7M | -59.09% | -66.59% | -230.39% | -$7.1M |
uniQure NV vs. Competitors
-
Which has Higher Returns QURE or ARGX?
argenx SE has a net margin of -1940.45% compared to uniQure NV's net margin of 15.95%. uniQure NV's return on equity of -154.29% beat argenx SE's return on equity of -6.01%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV55.36% -$0.91 $106.9M ARGXargenx SE89.7% $1.39 $4.3B -
What do Analysts Say About QURE or ARGX?
uniQure NV has a consensus price target of $30.54, signalling upside risk potential of 117.35%. On the other hand argenx SE has an analysts' consensus of $701.57 which suggests that it could grow by 9.53%. Given that uniQure NV has higher upside potential than argenx SE, analysts believe uniQure NV is more attractive than argenx SE.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV8 2 0 ARGXargenx SE13 2 0 -
Is QURE or ARGX More Risky?
uniQure NV has a beta of 0.412, which suggesting that the stock is 58.797% less volatile than S&P 500. In comparison argenx SE has a beta of 0.587, suggesting its less volatile than the S&P 500 by 41.304%.
-
Which is a Better Dividend Stock QURE or ARGX?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or ARGX?
uniQure NV quarterly revenues are $2.3M, which are smaller than argenx SE quarterly revenues of $573.2M. uniQure NV's net income of -$44.4M is lower than argenx SE's net income of $91.4M. Notably, uniQure NV's price-to-earnings ratio is -- while argenx SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 23.78x versus 21.00x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV23.78x -- $2.3M -$44.4M ARGXargenx SE21.00x -- $573.2M $91.4M
-
Which has Higher Returns QURE or MRUS?
Merus NV has a net margin of -1940.45% compared to uniQure NV's net margin of -848.67%. uniQure NV's return on equity of -154.29% beat Merus NV's return on equity of -47.97%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV55.36% -$0.91 $106.9M MRUSMerus NV-- -$1.46 $703.3M -
What do Analysts Say About QURE or MRUS?
uniQure NV has a consensus price target of $30.54, signalling upside risk potential of 117.35%. On the other hand Merus NV has an analysts' consensus of $86.07 which suggests that it could grow by 118.18%. Given that Merus NV has higher upside potential than uniQure NV, analysts believe Merus NV is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV8 2 0 MRUSMerus NV12 0 0 -
Is QURE or MRUS More Risky?
uniQure NV has a beta of 0.412, which suggesting that the stock is 58.797% less volatile than S&P 500. In comparison Merus NV has a beta of 1.104, suggesting its more volatile than the S&P 500 by 10.426%.
-
Which is a Better Dividend Stock QURE or MRUS?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or MRUS?
uniQure NV quarterly revenues are $2.3M, which are smaller than Merus NV quarterly revenues of $11.8M. uniQure NV's net income of -$44.4M is higher than Merus NV's net income of -$99.9M. Notably, uniQure NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 23.78x versus 67.53x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV23.78x -- $2.3M -$44.4M MRUSMerus NV67.53x -- $11.8M -$99.9M
-
Which has Higher Returns QURE or PHAR?
Pharming Group has a net margin of -1940.45% compared to uniQure NV's net margin of -1.38%. uniQure NV's return on equity of -154.29% beat Pharming Group's return on equity of -8.24%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV55.36% -$0.91 $106.9M PHARPharming Group90.89% -$0.02 $321.2M -
What do Analysts Say About QURE or PHAR?
uniQure NV has a consensus price target of $30.54, signalling upside risk potential of 117.35%. On the other hand Pharming Group has an analysts' consensus of $27.00 which suggests that it could grow by 169.73%. Given that Pharming Group has higher upside potential than uniQure NV, analysts believe Pharming Group is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV8 2 0 PHARPharming Group2 0 0 -
Is QURE or PHAR More Risky?
uniQure NV has a beta of 0.412, which suggesting that the stock is 58.797% less volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QURE or PHAR?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PHAR?
uniQure NV quarterly revenues are $2.3M, which are smaller than Pharming Group quarterly revenues of $74.8M. uniQure NV's net income of -$44.4M is lower than Pharming Group's net income of -$1M. Notably, uniQure NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 23.78x versus 2.60x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV23.78x -- $2.3M -$44.4M PHARPharming Group2.60x -- $74.8M -$1M
-
Which has Higher Returns QURE or PHVS?
Pharvaris NV has a net margin of -1940.45% compared to uniQure NV's net margin of --. uniQure NV's return on equity of -154.29% beat Pharvaris NV's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV55.36% -$0.91 $106.9M PHVSPharvaris NV-- -$0.85 -- -
What do Analysts Say About QURE or PHVS?
uniQure NV has a consensus price target of $30.54, signalling upside risk potential of 117.35%. On the other hand Pharvaris NV has an analysts' consensus of $34.08 which suggests that it could grow by 85.61%. Given that uniQure NV has higher upside potential than Pharvaris NV, analysts believe uniQure NV is more attractive than Pharvaris NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV8 2 0 PHVSPharvaris NV4 0 0 -
Is QURE or PHVS More Risky?
uniQure NV has a beta of 0.412, which suggesting that the stock is 58.797% less volatile than S&P 500. In comparison Pharvaris NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QURE or PHVS?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharvaris NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. Pharvaris NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PHVS?
uniQure NV quarterly revenues are $2.3M, which are larger than Pharvaris NV quarterly revenues of --. uniQure NV's net income of -$44.4M is higher than Pharvaris NV's net income of -$45.9M. Notably, uniQure NV's price-to-earnings ratio is -- while Pharvaris NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 23.78x versus -- for Pharvaris NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV23.78x -- $2.3M -$44.4M PHVSPharvaris NV-- -- -- -$45.9M
-
Which has Higher Returns QURE or PRQR?
ProQR Therapeutics NV has a net margin of -1940.45% compared to uniQure NV's net margin of -210.98%. uniQure NV's return on equity of -154.29% beat ProQR Therapeutics NV's return on equity of -66.59%.
Company Gross Margin Earnings Per Share Invested Capital QUREuniQure NV55.36% -$0.91 $106.9M PRQRProQR Therapeutics NV-- -$0.11 $32.9M -
What do Analysts Say About QURE or PRQR?
uniQure NV has a consensus price target of $30.54, signalling upside risk potential of 117.35%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $9.17 which suggests that it could grow by 286.78%. Given that ProQR Therapeutics NV has higher upside potential than uniQure NV, analysts believe ProQR Therapeutics NV is more attractive than uniQure NV.
Company Buy Ratings Hold Ratings Sell Ratings QUREuniQure NV8 2 0 PRQRProQR Therapeutics NV4 1 0 -
Is QURE or PRQR More Risky?
uniQure NV has a beta of 0.412, which suggesting that the stock is 58.797% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.727%.
-
Which is a Better Dividend Stock QURE or PRQR?
uniQure NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. uniQure NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QURE or PRQR?
uniQure NV quarterly revenues are $2.3M, which are smaller than ProQR Therapeutics NV quarterly revenues of $4.2M. uniQure NV's net income of -$44.4M is lower than ProQR Therapeutics NV's net income of -$8.9M. Notably, uniQure NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for uniQure NV is 23.78x versus 9.97x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QUREuniQure NV23.78x -- $2.3M -$44.4M PRQRProQR Therapeutics NV9.97x -- $4.2M -$8.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Express Stock Going Lower?
American Express Company (NYSE:AXP) has long been a Buffett favorite…
Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Buy
51
QRVO alert for Jan 18
Qorvo [QRVO] is up 14.47% over the past day.
Sell
31
ATEX alert for Jan 18
Anterix [ATEX] is up 11.14% over the past day.
